Premium
Involved field radiation therapy for early stage Hodgkin's disease in children. Preliminary results
Author(s) -
Cham William C.,
Tan Charlotte T. C.,
Martinez Alvaro,
Exelby Philip R.,
Tefft Melvin,
Middleman Patricia,
D'Angio Giulio J.
Publication year - 1976
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197604)37:4<1625::aid-cncr2820370402>3.0.co;2-n
Subject(s) - medicine , nodular sclerosis , stage (stratigraphy) , radiation therapy , surgery , disease , chemotherapy , diaphragm (acoustics) , laparotomy , lymphoma , paleontology , physics , hodgkin lymphoma , acoustics , loudspeaker , biology
Twenty Stage I and II children with Hodgkin's disease were treated with involved field radiation therapy. Twelve patients were Stage I. The histologic types were: nodular sclerosis (seven cases), mixed cellularity (two) and lymphocyte predominant (three). There were eight Stage II patients (six nodular sclerosis and two of mixed cellularity). One Stage I and 4 Stage II patients had class B disease. Involved field irradiation was used in these children after staging laparotomy showed no disease below the diaphragm. Eight of the 20 patients relapsed, five in lymph nodes adjacent to the primary site, two in areas across the diaphragm; the other had both local and distant extension. The median time to relapse after completion of radiation therapy for Stage I and II were 15 and 5 months, respectively. Two of the eight children with recurrent disease are dead. The other six were retreated and are alive and free of disease for periods ranging from 24 to 68 months after original treatment (median, 36 months). Two of the six survivors in this group received irradiation to the site of the recurrent disease only, one was given total nodal irradiation, and three had chemotherapy. The other 12 patients are in continuous first remission. They have been followed for a median time of 26 months. The actuarial relapse‐free survival and survival rates at 3 years are 57 and 89%, respectively.